These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37778965)

  • 41. Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer.
    Wang J; Chen Q; Wang X; Huang D; Jiang R
    J Comp Eff Res; 2023 May; 12(5):e230006. PubMed ID: 37067955
    [No Abstract]   [Full Text] [Related]  

  • 42. Corrigendum to "Regulation of fetal hemoglobin expression during hematopoietic stem cell development and its importance in bone metabolism and osteoporosis" [Int. Immunopharmacol. 57 (2018) 112-120].
    Kos O; Alexander C; Brandenburg K; Chen Z; Heini A; Heumann D; Khatri I; Mach JP; Rietschel ET; Terskikh A; Ulmer AJ; Waelli T; Yu K; Zähringer U; Gorczynski RM
    Int Immunopharmacol; 2018 Jun; 59():413. PubMed ID: 29681496
    [No Abstract]   [Full Text] [Related]  

  • 43. Corrigendum to "Different roles of bortezomib and ONX 0914 in acute kidney injury" [Int. Immunopharmacol. 82 (2020) 106259].
    Zhang XZ; Han F; Ding CG; Dou M; Wang YX; Xue WJ; Ding XM; Zheng J; Xu CX; Tian PX
    Int Immunopharmacol; 2024 Jan; 126():111189. PubMed ID: 38012900
    [No Abstract]   [Full Text] [Related]  

  • 44. Corrigendum to "Liproxstatin-1 alleviates LPS/IL-13-induced bronchial epithelial cell injury and neutrophilic asthma in mice by inhibiting ferroptosis" [Int. Immunopharmacol. 109 (2022) 108770].
    Bao C; Liu C; Liu Q; Hua L; Hu J; Li Z; Xu S
    Int Immunopharmacol; 2023 Feb; 115():109482. PubMed ID: 36610897
    [No Abstract]   [Full Text] [Related]  

  • 45. Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis.
    Hu R; Zhao Z; Shi Y; Shi M; Xia G; Yu S; Feng J
    J Thorac Dis; 2021 May; 13(5):2959-2967. PubMed ID: 34164187
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer.
    Fu S; Huang H; Shang K; Tu G; Zhong P; Li S; Zhu X; Peng S; Liu Y; Lu Z; Chen L
    Future Oncol; 2023 Jan; 19(2):147-158. PubMed ID: 36779488
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Corrigendum to "Evaluation of different types of adjuvants in a malaria transmission-blocking vaccine" [Int. Immunopharmacol. 131 (2024) 111817].
    Yu X; Min H; Yao S; Yao G; Zhang D; Zhang B; Chen M; Liu F; Cui L; Zheng L; Cao Y
    Int Immunopharmacol; 2024 Aug; 137():112260. PubMed ID: 38926073
    [No Abstract]   [Full Text] [Related]  

  • 48. Corrigendum to "Kujigamberol interferes with pro-inflammatory cytokine-induced expression of and N-glycan modifications to cell adhesion molecules at different stages in human umbilical vein endothelial cells" [Int. Immunopharmacol. 62 (2018) 313-325].
    Fukuhara S; Tanigaki R; Kimura KI; Kataoka T
    Int Immunopharmacol; 2021 Oct; 99():107992. PubMed ID: 34330057
    [No Abstract]   [Full Text] [Related]  

  • 49. Corrigendum to "Forecasting of Oxidant/Antioxidant levels of COVID-19 patients by using Expert models with biomarkers used in the Diagnosis/Prognosis of COVID-19" [Int. Immunopharmacol. 100 (2021) 108127].
    Huyut MT; Huyut Z
    Int Immunopharmacol; 2022 Dec; 113(Pt B):109457. PubMed ID: 36404254
    [No Abstract]   [Full Text] [Related]  

  • 50. Corrigendum to "Evaluation of the immunomodulatory and anti-inflammatory activity of Bakuchiol using RAW 264.7 macrophage cell lines and in animal models stimulated by lipopolysaccharide (LPS)" [Int. Immunopharmacol. 91 (2021) 107264].
    Kumar A; Sawhney G; Kumar Nagar R; Chauhan N; Gupta N; Kaul A; Ahmed Z; Sangwan PL; Satheesh Kumar P; Yadav G
    Int Immunopharmacol; 2022 Oct; 111():109003. PubMed ID: 35778365
    [No Abstract]   [Full Text] [Related]  

  • 51. Corrigendum to "Antcin A alleviates pyroptosis and inflammatory response in Kupffercells of non-alcoholic fatty liver disease by targeting NLRP3" [Int. Immunopharmacol. 100 (2021) 108126].
    Ruan S; Han C; Sheng Y; Wang J; Zhou X; Guan Q; Li W; Zhang C; Yang Y
    Int Immunopharmacol; 2022 Mar; 104():108485. PubMed ID: 34955407
    [No Abstract]   [Full Text] [Related]  

  • 52. Corrigendum to 'In-vitro and in-vivo anti-breast cancer activity of synergistic effect of berberine and exercise through promoting the apoptosis and immunomodulatory effects' [Int. Immunopharmacol. 87 (2020) 106787].
    Ma W; Zhang Y; Yu M; Wang B; Xu S; Zhang J; Li X; Ye X
    Int Immunopharmacol; 2020 Nov; 88():106899. PubMed ID: 32827917
    [No Abstract]   [Full Text] [Related]  

  • 53. Corrigendum to "Photothermic therapy with cuttlefish ink-based nanoparticles in combination with anti-OX40 mAb achieve remission of triple-negative breast cancer" [Int. Immunopharmacol. 115 (2023) 109622].
    Momenzadeh N; Hajian S; Shabankare A; Ghavimi R; Kabiri-Samani S; Kabiri H; Hesami-Zadeh K; Shabankareh ANT; Nazaraghay R; Nabipour I; Mohammadi M
    Int Immunopharmacol; 2023 Nov; 124(Pt B):111035. PubMed ID: 37858486
    [No Abstract]   [Full Text] [Related]  

  • 54. Corrigendum to "Asiatic acid from Potentilla chinensis alleviates non-alcoholic fatty liver by regulating endoplasmic reticulum stress and lipid metabolism". [Int. Immunopharmacol. 65 (2018) 256-267].
    Wang D; Lao L; Pang X; Qiao Q; Pang L; Feng Z; Bai F; Sun X; Lin X; Wei J
    Int Immunopharmacol; 2020 Jul; 84():106291. PubMed ID: 32094005
    [No Abstract]   [Full Text] [Related]  

  • 55. Corrigendum to "Pathogenesis of Concanavalin A induced autoimmune hepatitis in mice" [Int. Immunopharmacol. 102 (2022) 108411].
    Hao J; Sun W; Xu H
    Int Immunopharmacol; 2022 Mar; 104():108550. PubMed ID: 35067473
    [No Abstract]   [Full Text] [Related]  

  • 56. Corrigendum to "Inhibitory effect of 9-hydroxy-6,7-dimethoxydalbergiquinol from Dalbergia odorifera on the NF-кB-related neuroinflammatory response in lipopolysaccharide-stimulated mouse BV2 microglial cells is mediated by heme oxygenase-1" [Int Immunopharmacol (2013) 828-835].
    Lee DS; Li B; Keo S; Kim KS; Jeong GS; Oh H; Kim YC
    Int Immunopharmacol; 2016 Dec; 41():144. PubMed ID: 27852515
    [No Abstract]   [Full Text] [Related]  

  • 57. Corrigendum to "Icariin targets Nrf2 signaling to inhibit microglia-mediated neuroinflammation" [Int. Immunopharmacol. 73 (2019) 304-311].
    Zheng Y; Zhu G; He J; Wang G; Li D; Zhang F
    Int Immunopharmacol; 2020 Nov; 88():107004. PubMed ID: 32950402
    [No Abstract]   [Full Text] [Related]  

  • 58. Corrigendum to "Immune-enhancing effects of polysaccharides extracted from Lilium lancifolium Thunb" [Int. Immunopharmacol. 52 (2017) 119-126].
    Pan G; Xie Z; Huang S; Tai Y; Cai Q; Jiang W; Sun J; Yuan Y
    Int Immunopharmacol; 2018 May; 58():186. PubMed ID: 29599101
    [No Abstract]   [Full Text] [Related]  

  • 59. Corrigendum to "Circulating midkine in children with Henoch-Schönlein purpura: Clinical implications" [Int. Immunopharmacol. (2016) 246-250].
    Su Z; Lv X; Liu Y; Zhang J; Guan J; Gai Z
    Int Immunopharmacol; 2016 Dec; 41():145. PubMed ID: 27612398
    [No Abstract]   [Full Text] [Related]  

  • 60. Corrigendum to 'Protective effect of kobophenol A on nitric oxide-induced cell apoptosis in human osteoblast-like MG-63 cells: Involvement of JNK, NF-κB and AP-1 pathways' [Int. Immunopharmacol. 11 (2011) 1251-1259].
    Lee SR; Kwak JH; Park DS; Pyo S
    Int Immunopharmacol; 2019 Jan; 66():388. PubMed ID: 30473316
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.